Summary
Seven cases of crystalluria following primidone overdose have been reported since the 1950s. An eighth case of primidone crystalluria following overdose is presented. Because of low aqueous solubility (600 mg/L at 37°C) which is directly proportional to temperature, any factor increasing renal excretion of unchanged primidone predisposes to crystal formation. Renal clearance is dependent on dosage because of negligible protein binding, zero-order conversion to phenobarbitone (phenobarbital) and first-order conversion to phenylethylmalonamide. Therapy with other anticonvulsants known to induce the metabolism to phenobarbitone does not appear to be protective against crystalluria in overdose situations. The critical serum primidone concentration for crystalluria presence seems to be 80 mg/L. There is evidence for nephrotoxicity of the crystals themselves if formed in vivo (actual crystal presence during voiding). The chemical phenomenon of supersaturation of a solution is protective against in vivo crystal formation with subsequent nephrotoxicity. Vigorous hydration to augment elimination and to lessen the propensity for renal toxicity is recommended.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bailey DN, Jatlow PI. Chemical analysis of massive crystalluria following primidone overdose. American Journal of Clinical Pathology 58: 583–589, 1972
Brady JE, Holum JR. Quantitative aspects of chemical reactions — reactions in solution. In Brady et al. (Eds) Fundamentals of chemistry, pp. 98–99, John Wiley & Sons, New York, 1981
Brillman J, Gallagher BB, Mattson RH. Acute primidone intoxication. Archives of Neurology 30: 255–258, 1974
Cate JC, Tenser R. Acute primidone overdosage with massive crystalluria. Clinical Toxicology 8: 385–389, 1975
Cloyd JC, Miller K.W, Leppik IE. Primidone kinetics: effects of concurrent drugs and duration of therapy. Clinical Pharmacology and Therapeutics 29: 402–407, 1981
Gallagher BB, Baumel IP. Primidone: absorption, distribution and excretion. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 357–359, Raven Press, New York, 1972a
Gallagher BB, Baumel IP. Primidone: absorption, distribution and excretion. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 361–366, Raven Press, New York, 1972b
Gallagher BB, Baumel IP. Primidone: chemistry and methods for determination. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 253–256, Raven Press, New York, 1972c
Gallagher BB, Baumel IP, Mattson RH. Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration. Neurology 22: 1186–1192, 1972
Huisman JW. Disposition of primidone in man: an example of auto-induction of a human enzyme system? Pharmaceutical Weekblad 104: 799–802, 1969
Lagenstein I, Stemowsky HJ, Iffland E, et al. Intoxication with primidone: continuous monitoring of serum primidone and its metabolites during forced diuresis. Neuro-pädiatrie 8: 190–195, 1977
Matzke GR, Cloyd JD, Sawchuck RJ. Acute phenytoin and primidone intoxication: a pharmacokinetic analysis. Journal of Clinical Pharmacology 21: 92–99, 1981
Morley D, Wynne NA. Acute primidone poisoning in a child. British Medical Journal 1: 90, 1957
Sellers EM. Mechanisms of alcohol interactions with drugs. In Avogaro et al. (Eds) Metabolic effects of ethanol, pp. 113–118, Elsevier/North Holland Biomedical Press, Amsterdam, 1979
Turner CR. Primidone intoxication and massive crystalluria. Clinical Pediatrics 19: 706–707, 1980
van Heijst ANP, de Jong W, Seldenrijk R, et al. Coma and crystalluria: a massive primidone intoxication treated with haemoperfusion. Journal of Toxicology-Clinical Toxicology 20: 307–318, 1983
Zavadil P, Gallagher BB. Metabolism and excretion of 14C-primidone in epileptic patients. In Jang (Ed.) Epileptology, George Thieme Verlag KG, Stuttgart, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lehmann, D.F. Primidone Crystalluria Following Overdose. Med Toxicol Adverse Drug Exp 2, 383–387 (1987). https://doi.org/10.1007/BF03259955
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259955